Balyasny Asset Management LLC Eq Rx, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $4.7 Million - $6.54 Million	2,829,022 Added 1157.84%	3,073,359 $6.82 Million
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $352,581 - $429,230	218,995 Added 864.16%	244,337 $454,000
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $12,484 - $19,628	6,936 Added 37.68%	25,342 $49,000
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $37,732 - $101,233	18,406 New	18,406 $45,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.69 $196,112 - $348,711	-61,285 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $171,598 - $452,896	61,285 New	61,285 $253,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.